Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

  • Bishop N
  • Adami S
  • Ahmed S
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


BACKGROUND: Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. METHODS: In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2.5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov, number NCT00106028. FINDINGS: Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16.3% in the risedronate group and 7.6% in the placebo group (difference 8.7%, 95% CI 5.7-11.7; p

Author-supplied keywords

  • Administration
  • Adolescent
  • Alkaline Phosphatase
  • Alkaline Phosphatase: metabolism
  • Analysis of Variance
  • Bone Density
  • Bone Density Conservation Agents
  • Bone Density Conservation Agents: administration &
  • Bone Density Conservation Agents: adverse effects
  • Bone Density: drug effects
  • Child
  • Collagen
  • Collagen: metabolism
  • Double-Blind Method
  • Drug Administration Schedule
  • Etidronic Acid
  • Etidronic Acid: administration & dosage
  • Etidronic Acid: adverse effects
  • Etidronic Acid: analogs & derivatives
  • Female
  • Humans
  • Male
  • Oral
  • Osteogenesis Imperfecta
  • Osteogenesis Imperfecta: drug therapy
  • Osteogenesis Imperfecta: physiopathology
  • Preschool
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • Nick Bishop

  • Silvano Adami

  • S Faisal Ahmed

  • J Anton

  • Paul Arundel

  • Christine P Burren

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free